BioPharmSignal logoBioPharmSignal

Biotech News

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics (GPCR)Structure TherapeuticsEarnings

First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual amylin and calcitonin receptor agonist) and initiation of MAD clinical trial on

Related news

AVTXAvalo Therapeutics2026-08-06 11:00 EST

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

ACRSAclaris Therapeutics2026-08-06 10:59 EST

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

HCWBHCW Biologics2026-05-14 20:25 EST

HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

SNGXSOLIGENIX2026-08-07 11:30 EST

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

INMBINmune Bio2026-08-06 20:00 EST

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

IFRXInflarx NV2026-08-06 11:30 EST

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

KNSAKiniksa2026-07-28 11:30 EST

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

View all latest news

Structure Therapeutics

Structure-Based Metabolic Drug Discovery Structure Therapeutics develops oral small molecules against validated metabolic targets using structure-based drug design. Its franchise is intended to offer oral alternatives to injectable peptide therapies. Aleniglipron Aleniglipron is an oral GLP-1 receptor agonist in development for obesity...

Recent company news

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-06-05 20:05 EST

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

GPCRStructure Therapeutics2026-05-26 20:05 EST

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-04-27 20:05 EST

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

Stock data

Close
52.62 USD
Market cap
2.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States